In addition to our product candidates custirsen in Phase 3 development, and apatorsen (OGX-427) in Phase 2 development, our investigational compound OGX-225 is in pre-clinical development.
OGX-225 is a second generation antisense drug candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins -2 and -5 (IGFBP-2, IGFBP-5), two proteins that when overexpressed affect the growth of cancer cells.
Increased IGFBP-2 and IGFBP-5 production are observed in many human cancers, including prostate, breast, colorectal, non-small cell lung, glioblastoma, acute myeloid leukemia, acute lymphoblastic leukemia, neuroblastoma, and melanoma.
Increased IGFBP-2 and IGFBP-5 production are linked to faster rates of cancer progression, treatment resistance, and shorter survival duration in humans.
Preclinical studies with human prostate and breast cancer cells have shown that reducing IGFBP-2 and IGFBP-5 production with OGX-225 sensitized these tumor types to hormone ablation therapy or chemotherapy and induced tumor cell death.